Dr Andrew Stephens, OCRF Research Fellow

Biography

After completing a PhD in the Department of Biochemistry at Monash University, Dr Andrew Stephens undertook a postdoctoral position at the University of Sydney using proteomics to discover novel antibiotic targets in bacteria. In 2006, he returned to Melbourne to establish a proteomics laboratory at the Hudson Institute, under the guidance of Professor David Robertson. In 2009, he established the Ovarian Cancer Biomarker group to specifically drive new research into the design and development of diagnostic tools, to improve the detection and management of ovarian cancers.

Currently an Ovarian Cancer Research Foundation (OCRF) Research Fellow, Dr Stephens is passionate about reducing the mortality of ovarian cancer. A leading authority on the application of proteomics technologies, his work aims to better understand the development of ovarian tumours and identify specific biological events useful as markers of early-stage disease.

He is also working to improve treatment and management of the disease through development of novel targeted therapies.

Selected publications

  • Heng S, Stephens AN, Jobling TW, Nie G (2016) Total PC activity is increased in uterine lavage of post-menopausal endometrial but not ovarian cancer patients. J Cancer  7:1812-1814.

  • Heng S, Stephens AN, Jobling TW, Nie G (2016) Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget 7:46573-46578.

  • Stanton PG, Foo CFH, Rainczuk A, Stephens AN, Condina M, O’Donnell L, Weidner W, Ishikawa T, Cruickshanks L, Smith LB, McLachlan RI (2016) Mapping the testicular interstitial fluid proteome from normal rats. Proteomics 16:2391-402.

  • Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyles MA, Lis J, Gilks CB, Moss, P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell D, Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG (2015) Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6:37663-77.

  • Zhang H, Maqsudi S, Rainczuk A, Duffield N, Lawrence J, Keane FM, Justa-Schuch D, Geiss-Friedlander R, Gorrell MD, Stephens AN (2015) Identification of Novel Dipeptidyl Peptidase 9 Substrates by Two-Dimensional Differential In-Gel Electrophoresis. FEBS J 282:3737-57.

  • Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DDL, Campbell IG, Gorringe KL (2015) Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 7:87.

  • Rainczuk A, Rao JR, Gathercole JL, Fairweather NJ, Chu S, Masadah R, Jobling TW, Stephens AN (2014) Evidence for the Antagonistic Form of CXC-motif Chemokine CXCL10 in Serous Epithelial Ovarian Tumours. Int J Cancer 134:530-41.

  • Rainczuk A, Condina M, Pelzing M, Dolman S, Rao JR, Fairweather NJ, Jobling TW, Stephens AN (2013) The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine. J Proteome Res 12:4074-88.

  • Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN, Nie G (2013) HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors. J Cancer 4:152-64.

  • Rainczuk A, Rao J, Gathercole J, Stephens AN (2012) The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction 144:303-317.

  • Stanton PG, Sluka P, Foo CFH, Stephens AN, Smith AI, McLachlan RI, O’Donnell L (2012) Proteomic changes in rat spermatogenesis in response to in vivo androgen manipulation; impact on meiotic cells. PLOS One 7:e41718.

  • Singh H, Makino S, Endo Y, Li Y, Stephens AN, Nie G (2012) Application of the wheat-germ cell-free translation system to produce high temperature requirement A3 (HtrA3) proteases. Biotechniques 52:23-8.